-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Retension Pharmaceuticals with Buy Rating, Announces Price Target of $55

Benzinga·11/02/2026 14:05:13
语音播报
Guggenheim analyst Seamus Fernandez initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Buy rating and announces Price Target of $55.